Chief Medical Officer & Head of Research SanBio, Inc. East Melbourne, Victoria
Intracranial implantation of SB623 cells was safe and well tolerated in patients with chronic TBI, and was associated with statistically significant improvement in motor status at 24 weeks.
Upon completion, participants will be able to appreciate the importance of stem cell implantation as a potential treatment for traumatic brain injury.
Upon completion, participants will be able to understand that in this clinical trial, there were no statistically significant differences in safety between SB623 implantation and sham surgery controls.
Upon completion, participants will be able to understand that in this clinical trial, Fugl-Meyer Motor Scale score change from baseline to 24-weeks was significantly greater for SB623-implanted patients than controls.